We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+32.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$6.66B
AUM Growth
+$1.54B
Cap. Flow
+$235M
Cap. Flow %
3.53%
Top 10 Hldgs %
47.3%
Holding
121
New
27
Increased
30
Reduced
28
Closed
12

Top Buys

Rank Stock Value
1
KARD
Kardigan Inc
KARD
+$190M
2
AVLN
Avalyn Pharma
AVLN
+$77.2M
3
TNGX icon
Tango Therapeutics
TNGX
+$63.5M
4
RLAY icon
Relay Therapeutics
RLAY
+$63.2M
5
BIIB icon
Biogen
BIIB
+$52.8M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$209M
2
ASND icon
Ascendis Pharma A/S
ASND
+$85.9M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$37.6M
4
DYN icon
Dyne Therapeutics
DYN
+$36.8M
5
ABVX
Abivax
ABVX
+$28.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.3%
2 Miscellaneous 3.58%
3 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
26
PUT
Moderna
MRNA
$57.8B
$70M 1.05%
1,000,000
– –
DYN icon
27
Dyne Therapeutics
DYN
$4.56B
$59.7M 0.9%
2,689,235
-1,979,604
-42% -$36.8M
BIIB icon
28
Biogen
BIIB
$32.5B
$59.7M 0.9%
+276,173
New +$52.8M
IMVT icon
29
Immunovant
IMVT
$8.07B
$52.3M 0.79%
1,357,383
-240,000
-15% -$7.31M
UNH icon
30
UnitedHealth
UNH
$356B
$48.5M 0.73%
+116,806
New +$43.3M
XBI icon
31
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$47.5M 0.71%
+300,000
New +$40.6M
IONS icon
32
Ionis Pharmaceuticals
IONS
$9.78B
$44.9M 0.67%
566,000
+62,000
+12% +$4.67M
STRO icon
33
Sutro Biopharma
STRO
$336M
$43.3M 0.65%
1,304,846
+589,539
+82% +$18.4M
ANRO icon
34
Alto Neuroscience
ANRO
$1.41B
$42.5M 0.64%
1,609,893
-400,000
-20% -$9.25M
JAZZ icon
35
Jazz Pharmaceuticals
JAZZ
$16B
$41M 0.61%
170,000
– –
CRVS icon
36
Corvus Pharmaceuticals
CRVS
$1.23B
$39.9M 0.6%
2,667,441
+375,000
+16% +$5.2M
SION
37
Sionna Therapeutics
SION
$317M
$39.8M 0.6%
905,000
+246,561
+37% +$9.86M
CTMX icon
38
CytomX Therapeutics
CTMX
$791M
$39.1M 0.59%
10,439,185
+340,361
+3% +$1.3M
AORT icon
39
Artivion
AORT
$1.24B
$39M 0.59%
1,737,290
+100,000
+6% +$2.8M
XFOR icon
40
X4 Pharmaceuticals
XFOR
$404M
$37M 0.56%
7,933,491
+1,195,843
+18% +$4.91M
CORT icon
41
Corcept Therapeutics
CORT
$12B
$34.6M 0.52%
398,385
+348,385
+697% +$21M
RGEN icon
42
Repligen
RGEN
$9.49B
$33.9M 0.51%
248,212
-32,329
-12% -$3.97M
AVR
43
Anteris Technologies
AVR
$861M
$33.7M 0.51%
3,425,476
– –
RAPP
44
Rapport Therapeutics
RAPP
$2.24B
$32.2M 0.48%
773,342
+99,419
+15% +$3.65M
DMRA
45
Damora Therapeutics
DMRA
$1.74B
$31.8M 0.48%
1,223,000
– –
CRL icon
46
Charles River Laboratories
CRL
$13.8B
$31.8M 0.48%
+140,000
New +$24.9M
AXSM icon
47
Axsome Therapeutics
AXSM
$10.8B
$29M 0.44%
118,450
-31,500
-21% -$6.83M
EYPT icon
48
PUT
EyePoint Inc
EYPT
$398M
$28.6M 0.43%
+2,000,000
New +$26.8M
DBVT
49
DBV Technologies
DBVT
$850M
$27.1M 0.41%
1,653,350
+688,959
+71% +$13M
IRTC icon
50
iRhythm Holdings
IRTC
$4.01B
$26.6M 0.4%
223,766
+118,740
+113% +$13.8M
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGAL
K5 Global Advisor LLC Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Perceptive Advisors held 121 positions worth $6.66B, up 30% from $5.12B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $235M of net new capital in Q2 2026, opening 27 new positions and adding to 30 existing holdings. Its largest new stake was Kardigan Inc: 8,200,662 shares worth $196M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $85.9M trimmed.

  • Perceptive Advisors's largest Q2 2026 buy was Kardigan Inc: 8,200,662 shares worth $196M.
  • Perceptive Advisors added most to Tango Therapeutics in Q2 2026, an estimated $63.5M increase.
  • Perceptive Advisors's biggest Q2 2026 reduction was Ascendis Pharma A/S, cutting an estimated $85.9M.
  • Perceptive Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $209M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $6.66B portfolio in Q2 2026.
  • Perceptive Advisors opened 27 new positions and closed 12 in Q2 2026.
  • Perceptive Advisors's portfolio value rose 30% quarter-over-quarter to $6.66B.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.